Business
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder CancerThe collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1).Combination therapy aims to offer a complementary approach that may provide additional treatment options for patients with NMIBC.Collaboration reflects the shared commitment of Ferring and Theralase® to advance treatment options for NMIBC patients.Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) are pleased to announce that they have entered into a collaborative clinical development agreement (\"Agreement\"), on January 9, 2026. The Agreement builds on Theralase®'s existing clinical program (NCT03945162) with a new cohort investigating Theralase®'s investigational light-activated small molecule Ruvidar® (TLD-1433) in combination with Ferring's intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for adult patients diagnosed with high-risk Bacillus Calmette-Guérin (\"BCG\")-unresponsive Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\") with or without papillary tumors (±Ta/T1).Under the terms of the Agreement, Theralase® will remain the sponsor of the study, with both parties providing clinical overview of the new cohort through a joint development committee. The new cohort will be enrolled and treated in the United States and then subject to written agreement may expand into Canada or other countries. \"The introduction of ADSTILADRIN, as the first intravesical gene therapy, filled a critical unmet need for patients with BCG-unresponsive NMIBC who faced limited treatment options and needed an alternative to invasive bladder removal surgery,\" said Ashish Kamat, MD, MBBS, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center, Houston, Texas and President of the International Bladder Cancer Group. \"As the BCG-unrespo...